Chlorzoxazone API production capacity reduction

From the perspective of demand, currently, chlorzoxazone medicines on the market mainly include chlorzoxazone tablets and chlorzoxazone capsules, both of which are central muscle relaxants, chlorzoxazone tablets It is a prescription drug, while Chlorzoxazone capsules are OTC Class A double-cross drugs.

Chlorzoxazone raw materials can be made into various chlorzoxazone drugs including compound chlorzoxazone tablets, capsules and injections. Chlorzoxazone has a fast and long-lasting effect, small side effects, and almost no gastrointestinal irritation. It can be used in a compound with Paracetamol to improve the analgesic effect. It is clinically used to treat low back pain, neuralgia, rheumatoid arthritis, Acute and chronic soft tissue contusions, muscle strains, sprains, and spine diseases caused by muscle spasm and rigidity, the total effective rate is 98.59%.

The production of chlorzoxazone API has certain technical, environmental protection and qualification barriers. Due to the impact of stricter environmental protection policies and the increase of downstream alternative drugs, some companies have withdrawn from the chlorzoxazone API market, such as Jiangsu Shenlong Pharmaceutical Co., Ltd. and others, the overall production capacity of the chlorzoxazone API industry is also showing a downward trend. According to the "Market Development Status and Production and Sales Data Analysis Report of China's Chlorzoxazone API Industry in 2020-2024" released by the New Sijie Industry Research Center, in 2016, the production capacity of China's Chlorzoxazone API industry was 400 tons; in 2019 , The production capacity of China's chlorzoxazone API industry has been reduced to 350 tons.

At present, companies in the chlorzoxazone API industry mainly include Shandong Keyuan Pharmaceutical Co., Ltd., Henan Quanyu Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group, Shanghai Fudan Fuhua Pharmaceutical Co., Ltd., etc. The production scale is generally small , The degree of competition eases. Among them, the chlorzoxazone raw materials produced by Lunan Pharmaceutical Group and Shanghai Fudan Fuhua Technology Co., Ltd. are directly used in the company's internal drug production and are not sold to the outside world.

From the perspective of demand, currently, chlorzoxazone medicines on the market mainly include chlorzoxazone tablets and chlorzoxazone capsules, both of which are central muscle relaxants, chlorzoxazone tablets It is a prescription drug, while Chlorzoxazone capsules are OTC Class A double-cross drugs. In recent years, with the advancement of technology, the demand for chlorzoxazone drugs has increased year by year, and the demand for chlorzoxazone tablets is the majority. In 2019, China's demand for chlorzoxazone API was 102 tons, a year-on-year increase of 4.0%.

Industry researchers from New Ideas said that although stricter environmental protection policies have put pressure on the development of the industry, they have also brought investment opportunities. In recent years, stricter environmental protection policies and rising production costs have caused some small-scale, backward-processed, and poor-pollution control companies in the chlorzoxazone API industry to gradually withdraw from the market. Market competition has eased, and product prices have risen as a whole. Profitability improved. In the future, companies with environmentally friendly technology will have an advantage in the market. Therefore, companies should increase their research investment in environmentally friendly technology.